The Pulse Check

Aug 20, 2026

•

3 min read

Cancer Vaccine on the Cards

Jason Segal

The Pulse Check

Aug 19, 2026

•

3 min read

The Healthcare Cerberus Just Woke Up

Jason Segal

Neuren Pharmaceuticals (ASX: NEU)

The Orphan Drug Playbook: The Neuren Story (NEU)

Aug 18, 2026

•

10 min read

The Orphan Drug Playbook: The Neuren Story (NEU)

Jason Segal

The Pulse Check

Reporting Season: What I look for in Annual Reports

Aug 17, 2026

•

8 min read

Reporting Season: What I look for in Annual Reports

Jason Segal

The Pulse Check

Aug 14, 2026

•

2 min read

Two weeks to go...

Jason Segal

The Pulse Check

Back the Jockey: The Alterity Story (ASX: ATH)

Aug 13, 2026

•

8 min read

Back the Jockey: The Alterity Story (ASX: ATH)

Jason Segal

The Pulse Check

Aug 7, 2026

•

2 min read

Day 2 of Bioshares: One Year On...

Jason Segal

The Pulse Check

Aug 6, 2026

•

1 min read

Eli Lilly's $23 Billion Shopping Spree

Jason Segal

The Pulse Check

Aug 5, 2026

•

1 min read

Day 1 of Bioshares: It’s Snow Problem

Jason Segal

The Pulse Check

Aug 4, 2026

•

8 min read

The Money Equation for Biotechs

Jason Segal

The Pulse Check

Aug 3, 2026

•

9 min read

Time is Brain: The EMVision Story (EMV)

Jason Segal

The Pulse Check

Control Bionics: A Quarter’s Worth of Progress

Jul 31, 2026

•

5 min read

Control Bionics: A Quarter’s Worth of Progress

Jason Segal

The Pulse Check

The Biggest Tree in Healthcare Stands Tall

Jul 30, 2026

•

2 min read

The Biggest Tree in Healthcare Stands Tall

Jason Segal

Emyria (ASX: EMD)

Jul 29, 2026

•

3 min read

The Human Side to Healthcare Investing

Jason Segal

The Pulse Check

Jul 28, 2026

•

12 min read

Armchair on stage at Bio Connections

Jason Segal

The Pulse Check

Deep Cuts from the Surgeon: What happened with EBR?

Jul 27, 2026

•

3 min read

Deep Cuts from the Surgeon: What happened with EBR?

Jason Segal

The Pulse Check

Jul 24, 2026

•

3 min read

FDA gives the green light to peptides

Jason Segal

The Pulse Check

Designer Genes: The PYC Therapeutics Story (PYC)

Jul 23, 2026

•

10 min read

Designer Genes: The PYC Therapeutics Story (PYC)

Jason Segal

The Pulse Check

Tetratherix (TTX) Quarterly: 4Cing a Big Year

Jul 22, 2026

•

4 min read

Tetratherix (TTX) Quarterly: 4Cing a Big Year

Jason Segal

The Pulse Check

The Guys Who Make Your TV Just Bet $1.8B on Peptides

Jul 21, 2026

•

3 min read

The Guys Who Make Your TV Just Bet $1.8B on Peptides

Jason Segal

The Pulse Check

Placebo Your Bets: Prediction Markets Enter Biotech

Jul 20, 2026

•

7 min read

Placebo Your Bets: Prediction Markets Enter Biotech

Jason Segal

Emyria (ASX: EMD)

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Jul 17, 2026

•

5 min read

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Jason Segal

The Pulse Check

Jul 16, 2026

•

8 min read

How CMC Makes or Breaks a Biotech

Jason Segal

Neurotech International (ASX: NTI)

The Long Way Round: The Neurotech International Story (NTI)

Jul 15, 2026

•

10 min read

The Long Way Round: The Neurotech International Story (NTI)

Jason Segal

The Pulse Check

Jul 14, 2026

•

3 min read

A Peptidal Wave is Coming

Jason Segal

The Pulse Check

Cancer Vaccine on the Cards

The Healthcare Cerberus Just Woke Up

The Orphan Drug Playbook: The Neuren Story (NEU)

Reporting Season: What I look for in Annual Reports

Two weeks to go...

Back the Jockey: The Alterity Story (ASX: ATH)

Day 2 of Bioshares: One Year On...

Eli Lilly's $23 Billion Shopping Spree

Day 1 of Bioshares: It’s Snow Problem

The Money Equation for Biotechs

Time is Brain: The EMVision Story (EMV)

Control Bionics: A Quarter’s Worth of Progress

The Biggest Tree in Healthcare Stands Tall

The Human Side to Healthcare Investing

Armchair on stage at Bio Connections

Deep Cuts from the Surgeon: What happened with EBR?

FDA gives the green light to peptides

Designer Genes: The PYC Therapeutics Story (PYC)

Tetratherix (TTX) Quarterly: 4Cing a Big Year

The Guys Who Make Your TV Just Bet $1.8B on Peptides

Placebo Your Bets: Prediction Markets Enter Biotech

Eli Lilly Enters Psychedelics: The Year of the Mushroom

How CMC Makes or Breaks a Biotech

The Long Way Round: The Neurotech International Story (NTI)

A Peptidal Wave is Coming

The Armchair Analyst